Browsing by Author Brunetto, M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 7 of 7
TitleAuthor(s)Issue Date
 
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Journal:Journal of Hepatology
Agarwal, KBrunetto, MSeto, WKWLim, YSFung, SMarcellin, PAhn, SHIzumi, NChuang, WLBae, HSharma, MJanssen, HPan, CCelen, MKFurusyo, NShalimar, DYoon, KTTrinh, HChan, HL
2018
 
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
Journal:PLoS One
Pan, CQChang, TTBae, SHBrunetto, MSeto, WKCoffin, CSTan, SKMo, SFlaherty, JFGaggar, ANguyen, MHCelen, MKThompson, AGane, EJBulterys, M
2021
 
Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study. Poster Presentation (SAT422)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Yuen, RMFAsselah, TJacobson, IMBrunetto, MJanssen, HTakehara, THou, JLKakuda8, TLambrecht, TKalmeijer, RGuinard-Azadian, CMayer, CJerzorwski, JVerbinnen, TLenz, OShukla, UBiermer, M
2022
 
HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY
Journal:Gastroenterology
Sonneveld, MJChiu, S-MPark, JYBrakenhoff, SMKaewdech, ASeto, WKTanaka, YCarey, IPapatheodoridi, MColombatto, PVan Bömmel, FJanssen, HLBerg, TZoulim, FAhn, SHDalekos, GNErler, NSBrunetto, MWedemeyer, HCornberg, MYuen, MFAgarwal, KBoonstra, AButi, MPiratvisuth, TPapatheodoridis, GChen, C-HMaasoumy, B
26-Sep-2023
 
Lower Pre-Treatment HBV DNA Levels Are Associated With Better Off-Treatment Outcomes After Nucleo(S)Tide Analogue Withdrawal In Patients With Chronic Hepatitis B
Proceeding/Conference:Hepatology
Sonneveld, MJChiu, SMPark, JYBrakenhoff, SKaewdech, ASeto, WKTanaka, YCarey, IPapatheodoridi, MColombatto, PVan Bommel, FBerg, TZoulim, FAhn, SHDalekos, GNErler, NSBrunetto, MWedemeyer, HCornberg, MYuen, MFAgarwal, KBoonstra, AButi, MPiratvisuth, TPapatheodoridis, GVChen, CHMaasoumy, B
31-Oct-2022
 
Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use
Proceeding/Conference:Journal of Hepatology
Gane, ESeto, WKWJanssen, HCarantu, FAKim, HJAbdurakhmanov, DNishiguchi, SAndrzej, HBae, HMo, SSuri, VGaggar, AFlaherty, JFKao, JHBrunetto, MFerret, MB
2018
 
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Journal:The Lancet Gastroenterology & Hepatology
Buti, MGane, ESeto, WKWChan, HLChuang, WLStepanova, THui, AJLim, YSMehta, RJanssen, HAcharya, SKFlaherty, JMassetto, BCathcart, ALKim, KGaggar, ASubramanian, GMMcHutchison, JPan, CBrunetto, MIzumi, NMarcellin, P
2016
Showing results 1 to 7 of 7